Cellectis SA (CLLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cellectis SA (CLLS) has a cash flow conversion efficiency ratio of -0.138x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.47 Million) by net assets ($75.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cellectis SA - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Cellectis SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cellectis SA (CLLS) financial obligations for a breakdown of total debt and financial obligations.
Cellectis SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cellectis SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CompX International Inc
NYSE MKT:CIX
|
0.087x |
|
Incap Oyj
HE:ICP1V
|
0.046x |
|
Transcontinental Inc
TO:TCL-A
|
0.002x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.023x |
|
Liaoning Kelong Fine ChemicalInc
SHE:300405
|
0.005x |
|
Forcecon Technology Co Ltd
TWO:3483
|
-0.009x |
|
Lionheart Holdings Unit
NASDAQ:CUBWU
|
-0.001x |
|
Resolute Holdings Management, Inc.
NASDAQ:RHLD
|
1.433x |
Annual Cash Flow Conversion Efficiency for Cellectis SA (2007–2025)
The table below shows the annual cash flow conversion efficiency of Cellectis SA from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Cellectis SA stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $75.90 Million | $-40.14 Million | -0.529x | -413.49% |
| 2024-12-31 | $131.03 Million | $22.10 Million | 0.169x | +157.73% |
| 2023-12-31 | $84.69 Million | $-24.75 Million | -0.292x | +57.92% |
| 2022-12-31 | $125.94 Million | $-87.44 Million | -0.694x | -57.03% |
| 2021-12-31 | $236.47 Million | $-104.56 Million | -0.442x | -70.15% |
| 2020-12-31 | $308.85 Million | $-80.26 Million | -0.260x | -33.61% |
| 2019-12-31 | $355.47 Million | $-69.14 Million | -0.195x | -28.54% |
| 2018-12-31 | $450.27 Million | $-68.14 Million | -0.151x | +17.32% |
| 2017-12-31 | $285.90 Million | $-52.33 Million | -0.183x | -61.34% |
| 2016-12-31 | $274.05 Million | $-31.09 Million | -0.113x | -1024.12% |
| 2015-12-31 | $288.22 Million | $3.54 Million | 0.012x | -98.25% |
| 2014-12-31 | $72.39 Million | $50.74 Million | 0.701x | +118.19% |
| 2013-12-31 | $6.65 Million | $-25.63 Million | -3.854x | -1105.67% |
| 2012-12-31 | $81.69 Million | $-26.11 Million | -0.320x | +10.29% |
| 2011-12-31 | $37.02 Million | $-13.19 Million | -0.356x | +15.35% |
| 2010-12-31 | $50.13 Million | $-21.10 Million | -0.421x | -337.25% |
| 2009-12-31 | $73.22 Million | $-7.05 Million | -0.096x | -350.06% |
| 2008-12-31 | $46.21 Million | $1.78 Million | 0.038x | +129.82% |
| 2007-12-31 | $43.54 Million | $-5.62 Million | -0.129x | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more